{"url_path":"/sec/ima/8-k/2026-06-17/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1835579/0001193125-26-274139-index.html","accession_number":"0001193125-26-274139","cik":"0001835579","ticker":"IMA","issuer_name":"ImageneBio, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1835579/0001193125-26-274139-index.html","primary_entity_key":"0001835579","primary_entity_name":"ImageneBio, Inc."},"word_count":251,"has_tables":true,"body_markdown":"Item 5.02\n\nDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\n(e)\n\nOn June 16, 2026, ImageneBio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As further described in Item 5.07 below, the stockholders of the Company approved an amendment and restatement of the Company’s 2025 Equity Incentive Plan (the “2025 Plan”) at the Annual Meeting to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the 2025 Plan by 850,000 shares and to include shares of common stock issuable upon conversion or exercise of convertible preferred stock and prefunded warrants in the calculation of the annual automatic share reserve increase (the “Amended Plan”). The Company’s Board of Directors had previously approved the amendment and restatement of the 2025 Plan, subject to stockholder approval.\n\nA description of the material terms of the Amended Plan is contained in the section entitled “Proposal 3: Approval of the Amendment and Restatement of the 2025 Equity Incentive Plan” of the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission on April 30, 2026 (the “Proxy Statement”). That description is incorporated into this Item 5.02 by reference. Such description, as well as the foregoing description in this Item 5.02, does not purport to be complete, and are qualified in their entirety by reference to the full text of the Amended Plan, which is attached hereto as Exhibit 10.1."}